English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
インデックス付き
- アカデミックキー
- レフシーク
- ハムダード大学
- パブロン
- ユーロパブ
- ICMJE
役立つリンク
オープンアクセスジャーナル
このページをシェアする
抽象的な
Bevacizumab (Bmab) +Dihydropyrimidine Dehydrogenase (DPD) Inhibitory Fluor pyrimidine (DIF) Combined Chemotherapy for the Treatment of Late-Stage Elderly Patients with Advanced/Recurrent Colorectal Cancer (ARCC)
Kazuma Kobayashi
Objective: In Japan, the elderly represent more than 20% of the total population. The incidence of elderly patients with advanced/recurrent colorectal cancer (ARCC) has also increased. However, the optimal regimen for elderly patients, particularly those over 75 years of age (advanced elderly), has not been established.
Results: The STD was 979 days, the median PFS was 350 days, and the RR was 23.3%. Grade ≥3 AEs with each regimen were: Bob + DIF, 1.9%, other regimens, 14.4%. Although no significant difference was observed in OS or PFS between Bmab + DIF and other treatment regimens, the transition rate to 2nd line chemotherapy after disease progression after first-line treatment was higher with Bmab + DIF (54.6% [6/11]) than with other treatment regimens (38.9% [7/18]); however, this difference did not reach statistical significance